| dc.description.abstract |
Psoriasis is a chronic autoimmune skin disorder that affects millions of people across the planet. It causes many serious complications to afflicted patients and is indicated by uncontrolled growth and differentiation of keratinocytes. Conventional dosage forms have been used for the topical delivery of antipsoriatic drugs but they possess their own limitations. These include poor patient compliance, inadequate penetration and targeting to diseased skin, and local toxicity. In recent decades nanocarriers like liposomes, micelles, and solid lipid nanoparticles have shown potential in delivering antipsoriatic active compounds to the targeted areas of skin. Such novel formulations improve therapeutic efficacy, increase localization of drug in the skin, and decrease side effects. This chapter sheds light on the current advancements in the field of nanocarriers in treating the psoriatic skin condition. |
en_US |